Phillip J. Koo, MD

Phillip J. Koo, MD

Banner MD Anderson Cancer Center

Phoenix, Arizona

Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian and his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System in Philadelphia, Pennsylvania. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM). His academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven motion correction. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. In 2022, Dr. Koo was the recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award.

Talks by Phillip J. Koo, MD

Differentiating PSMA Diagnostics & Therapeutics

Differentiating PSMA Diagnostics & Therapeutics

| Nov 2024

Phillip J. Koo, MD, examines radiopharmaceuticals, addressing trends and challenges in imaging and therapeutics. In this 11-minute presentation, Dr. Koo theorizes that radiology’s commoditization, accelerated by private equity and shifting toward high-volume, low-quality imaging, has raised concerns about diagnostic consistency.

Dr. Koo shares that the accessibility of PSMA PET imaging has rapidly expanded in the US. High utilization rates have led to issues of potential overuse and over-treatment, underscoring the need for more deliberate clinical decision-making. Variable imaging quality, often tied to the facility’s focus on throughput over accuracy, presents risks in diagnostics and patient outcomes. His presentation calls for ongoing advancements in both technology and professional collaboration to fully realize these tools’ therapeutic and diagnostic value.

Read More
PSMA PET Imaging

PSMA PET Imaging

| Aug 2024

Phillip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive of Oncology at the Banner MD Anderson Cancer Center in Phoenix, Arizona, presents a primer for urologists and oncologists on prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) imaging. Dr. Koo asserts that PSMA-PET is rapidly becoming a modern-day practice. He explains that not all hotspots shown on these scans are necessarily prostate cancer; sharing research demonstrating PSMA-PET images, including normal images and other findings, that are not prostate cancer. If a practitioner is uncertain, magnetic resonance imaging (MRI) can be performed. Dr. Koo highlights solitary rib lesions, which can present a challenge to clinicians due to a high proportion of false positives on the PSMA-PET scan. He then emphasizes that what is seen on the scan is only half the story, explaining that how technicians window, fuse, and send images can affect what a practitioner sees. Dr. Koo recommends that practitioners avoid sole reliance on the fused images. Practitioners should reach out to radiologists in order to gain clinical context and the opportunity to educate and learn from those experts. He then addresses variability in standard uptake value (SUV) and cites a study on the repeatability of SUV in oncologic 18F-FDG PET, concluding that practitioners should be very careful with SUV numbers and take them in context. Dr. Koo shares a scoring system for various PSMA-PET findings and calls this a clear, standardized way for practitioners to communicate with referring physicians. Finally, Dr. Koo addresses RADAR VI and VII as well as procedure guidelines for PSMA-PET.

Read More
PET Tumor Board Case: Gleason Grade 2 PCa After Multiple Treatments for BPH

PET Tumor Board Case: Gleason Grade 2 PCa After Multiple Treatments for BPH

| Jul 2024

In this discussion, E. David Crawford, MD, Jack A. Vickers Director of Prostate Research and Professor of Urology at the University of California, San Diego, leads a discussion of the case study of a healthy 69-year-old male with a history of multiple BPH treatments presenting with Gleason Grade 2 prostate cancer.

Read More
PET Tumor Board Case 4: Rapid Rise in PSA

PET Tumor Board Case 4: Rapid Rise in PSA

| Jun 2024

In this discussion, E. David Crawford, MD, Professor of Urology and Jack A. Vickers Director of Prostate Research at the University of California, San Diego, leads a discussion of the case study of a healthy 80-year-old male with a history of BPH presenting with a rapid rise of PSA from a PSA of 3-4 ng/ml to 9.7 ng/ml and increased urgency and perception of difficulty fully voiding.

Read More